NEW YORK (GenomeWeb) – ERS Genomics, a CRISPR/Cas9 commercialization vehicle, has licensed the genome editing technology to Swiss industrial biotech firm Evolva. Under the terms of the worldwide, non-exclusive licensing agreement, Evolva has the right to use the technology in engineering yeast and fungi for biomanufacturing purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.